NanoDynamics

NanoDynamics was a diversified nanotechnology company that operated a specialized life sciences division focused on advanced drug delivery systems. The company's primary pharmaceutical focus was the development of nanoparticle-based formulations of existing chemotherapeutic agents to improve efficacy and reduce toxicity. Its lead candidate, ND-001, was a nanoparticle formulation of paclitaxel designed to target solid tumors more effectively than conventional delivery methods. Despite significant early interest and a diverse portfolio of nanotech applications, the company faced financial difficulties and filed for Chapter 7 bankruptcy in 2009.